(ENTX) Entera Bio Ltd. PESTLE Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ENTX) Entera Bio Ltd. Complete Analysis Pack
Skip the Research. Get the Strategy.
This Entera Bio Ltd. PESTLE Analysis explains the political, economic, social, technological, legal, and environmental forces shaping the company and why that matters for strategy and investment. This page shows a real preview of the report so you can judge style and depth; purchase the full version to get the complete, ready-to-use company-specific analysis.
Political factors
Israel headquarters
Entera Bio is headquartered in Jerusalem, so Israeli domestic policy, tax rules, and life-science grants can affect hiring, funding, and clinical execution. Israel spends about 6.0% of GDP on R&D, one of the highest rates globally, which supports biotech talent and trial support. Regional security shifts can still disrupt site access, shipments, and patient visits.
Clinical-stage regulation
Entera Bio Ltd.'s programs are in Phase I and Phase II, so health regulators and ethics boards can shape every trial step, from site start-up to protocol edits. In the U.S., FDA IND reviews and IRB approvals can add weeks or months, and a single amendment can reset timelines. Political support for biotech R&D matters because faster reviews can speed data readouts and capital use.
Cross-border partnership with Amgen
Entera Bio Ltd.’s pact with Amgen Inc., a U.S. biotech with sales in 100+ countries, makes this political risk global. Cross-border value depends on trade policy, IP rules, and fast regulatory alignment between the U.S. and Israel, plus any changes in U.S. science funding or drug pricing rules. Strong diplomatic ties can lower friction, but any export, tax, or data-sharing shift can slow partner value.
Healthcare priority area
Hypoparathyroidism, osteoporosis, and fracture repair are high-need areas: osteoporosis affects about 200 million people worldwide, and fragility fractures exceed 8.9 million a year. Public health systems often favor therapies that address severe unmet need and long-term disability.
For Entera Bio Ltd, this policy bias can support adoption if its medicines show clear clinical value and lower downstream costs, especially in chronic care settings where fracture risk drives hospital use and rehab spending.
- 200 million people live with osteoporosis worldwide.
- 8.9 million fragility fractures occur each year.
- Access-focused policy can speed uptake.
Public funding environment
Entera Bio Ltd. benefits from Israel’s strong public R&D base: national gross R&D spending was about 6.3% of GDP in 2023, one of the highest in the OECD. That kind of state support helps biopharma firms access grants, incubators, and early research funding before revenues arrive. Still, if public budgets tighten, non-dilutive capital can shrink fast.
Israel supports early-stage biotech.
Public funding can cut dilution risk.
Budget swings can slow R&D financing.
Israel Policy, FDA Timing, and Security Risks Shape Entera Bio’s Outlook
Entera Bio Ltd. faces political risk from Israeli policy, tax, and grant changes, since Israel still backs biotech with high R&D spend. Its cross-border work with Amgen Inc. also depends on U.S.-Israel trade, IP, and data rules. FDA and IRB timing can shift trial starts and amendment cycles. Regional security can disrupt sites and shipments.
| Factor | Latest data | Impact |
|---|---|---|
| Israel R&D | 6.3% of GDP, 2023 | Supports grants and talent |
| Osteoporosis need | 200M people | Can favor access policies |
| Fragility fractures | 8.9M a year | Raises public-health demand |
What is included in the product
Detailed Word Document
Maps the key Political, Economic, Social, Technological, Environmental, and Legal forces shaping Entera Bio Ltd.’s risks, opportunities, and strategy.
Customizable Excel Spreadsheet
A concise Entera Bio Ltd. PESTLE summary that simplifies external risk review and speeds strategic planning.
Reference Sources
Provides a concise, traceable list of primary sources and industry data that speeds investor due diligence on Entera Bio Ltd.
Economic factors
2 lead drug programs
Entera Bio’s pipeline is still centered on two lead programs, EB612 and EB613, so R&D spend and management focus stay concentrated. That lowers operating complexity, but it also makes the Company more exposed to any setback in just one asset. In 2025, each milestone on EB612 or EB613 carried outsized economic value because there are only 2 shots on goal.
Clinical-stage business model
Entera Bio Ltd has no marketed product, so commercial drug sales were 0 in 2025 and the business still depended on R&D spending, not product cash flow.
For clinical-stage biopharma, external funding is the key economic driver: equity raises, grants, and partner cash help cover trial costs long before approval.
That makes cash runway and access to capital critical; if financing tightens, trial pace slows and dilution risk rises.
Phase II to Phase I transition
Entera Bio Ltd. is shifting EB613 from Phase II osteoporosis work into Phase I for non-healing fractures while EB612 stays in Phase II, so R&D burn stays high across both programs. Trial steps like this usually lift valuation expectations, but they also add spending on studies, GMP manufacturing, and FDA/EMA work; Entera Bio Ltd. reported a 2024 cash balance of about $22.6 million, underscoring how much funding the pipeline still needs.
Partnership-driven economics
Entera Bio Ltd.'s Amgen collaboration can bring non-dilutive cash through research funding and licensing economics, which helps cut the company’s standalone R&D burden. Deals like this also act as external validation of Entera Bio Ltd.’s platform, which can support partner interest and lower future funding pressure.
Any milestone or royalty stream would add upside without immediate equity dilution, improving Entera Bio Ltd.’s funding flexibility if programs advance. That matters most when cash needs rise before product revenue starts.
- Non-dilutive support reduces dilution risk
- Partner validation can ease future fundraising
- Milestones and royalties add flexible upside
Small-cap biotech funding pressure
Small-cap biotech funding stays tight for Entera Bio Ltd because loss-making drug developers still trade on trial news, not steady cash flow. Higher rates keep capital expensive: the U.S. federal funds target stayed at 5.25% to 5.50% through much of 2025, so equity raises can be more dilutive and debt harder to secure.
- Trial data can move sentiment fast.
- High rates lift funding costs.
- Small caps face tougher dilution.
Entera Bio’s Cash Burn Keeps Dilution Risk in Focus
Entera Bio Ltd. remains economically dependent on external capital because it had no product revenue in 2025 and kept funding EB612 and EB613 through R&D spend. The Company’s 2024 cash balance was about $22.6 million, so runway and dilution risk stay central. Higher rates in 2025 also kept biotech funding costly, which can slow trial pace if markets tighten.
| Key economic item | 2025/2024 data |
|---|---|
| Product revenue | 0 in 2025 |
| Cash balance | About $22.6 million in 2024 |
| Lead programs | EB612 and EB613 |
| Rate backdrop | 5.25% to 5.50% federal funds target in 2025 |
Preview Before You Purchase
Entera Bio Ltd. PESTLE Analysis
The preview shown here is the exact Entera Bio Ltd. PESTLE analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic or investment decisions.
Sociological factors
Unmet-need indications
EB612 targets hypoparathyroidism, a rare disorder with about 70,000 people affected in the U.S., while EB613 targets osteoporosis and non-healing fractures, where fracture nonunion affects roughly 5% to 10% of broken bones. These conditions can cut mobility, independence, and day-to-day quality of life. Patient demand stays high because current treatments often fail to restore normal bone and calcium balance.
Age-related bone disease
People aged 65+ are set to hit 1.6 billion by 2050, up from 771 million in 2022, and osteoporosis causes about 8.9 million fractures each year worldwide. As people live longer, bone-loss and slow fracture repair become bigger social issues, with mobility and independence at stake. That gives Entera Bio Ltd. a clear role in therapies that help healing and cut complications.
Oral treatment preference
Entera Bio Ltd.’s oral large-molecule focus fits a strong social shift toward easier dosing, since pills are usually simpler than injections or infusions. In chronic care, better convenience can lift adherence, and adherence matters because even small drops can worsen outcomes and raise care costs. This preference supports demand for oral options as patients and caregivers look for less disruptive treatment routines.
Chronic disease burden
Chronic disease burden supports Entera Bio Ltd. because its targets are long-term, recurring conditions that need steady therapy. WHO says chronic diseases cause about 74% of global deaths, so demand for effective, tolerable treatments stays high. Patients also want daily-life fit, which favors oral, convenient options over complex regimens.
- 74% of global deaths are chronic.
- Long-term illness drives repeat treatment need.
- Convenience shapes patient choice.
Specialist-driven adoption
Entera Bio Ltd.'s uptake depends on endocrinologists and orthopedists, because osteoporosis and related bone-loss care is specialist-led. Physician trust, guideline support, and real-world fracture data will drive adoption, especially with osteoporosis affecting about 10 million Americans and causing more than 2 million fractures each year. Education and evidence are central to switching care patterns.
- Specialists control prescribing.
- Guidelines shape uptake.
- Real-world outcomes matter most.
- Evidence must beat inertia.
Aging and fractures fuel demand for simpler oral bone care
Entera Bio Ltd. benefits from aging societies: people 65+ should reach 1.6 billion by 2050, and osteoporosis already drives about 8.9 million fractures a year worldwide. Patients with hypoparathyroidism and fracture nonunion want simpler, oral care that fits daily life, so convenience can lift adherence. Specialist-led prescribing and guideline support will still decide uptake.
| Factor | Key data |
|---|---|
| Aging | 1.6B aged 65+ by 2050 |
| Fractures | 8.9M yearly worldwide |
| Adherence | Oral dosing improves fit |
Technological factors
Oral large-molecule platform
Entera Bio’s oral large-molecule platform targets a hard problem: peptides and proteins usually break down in the GI tract, and many oral candidates have bioavailability below 1%. That makes platform performance the key moat, because even small gains in absorption can change dose, safety, and efficacy. In 2025, this is still one of the toughest drug-delivery tasks in biotech, with oral biologics remaining a small share of the pipeline.
EB612 Phase II
EB612 is in Phase II clinical testing for hypoparathyroidism, where companies usually look for early efficacy signals and dose response before a larger trial. Phase II results can support later-stage development if they show meaningful control of calcium levels and safety. For Entera Bio Ltd., this stage matters because Phase II data often drive the next funding and trial-design decision.
EB613 Phase I
EB613 has finished Phase II in osteoporosis and is now in Phase I for non-healing bone fractures, so Entera Bio Ltd. is adding fresh safety and proof-of-concept data before it can widen use. That multi-indication push matters because fracture healing has a different risk profile than osteoporosis, and early-stage studies usually track safety plus dose response in small patient groups.
Biologics formulation complexity
Biologics oral delivery is still a hard science: proteins and peptides are fragile, and oral bioavailability for semaglutide is only about 0.4% to 1%, so tiny gains can change program economics fast. Entera Bio Ltd. needs tight control of stability, absorption enhancers, and batch-to-batch consistency. Scale-up is just as important, because a formula that works in the lab can fail in manufacturing.
- 0.4%-1% oral semaglutide bioavailability
- Stability drives oral biologic success
- Scale-up risk can kill value
Research collaboration with Amgen
The Amgen pact gives Entera Bio Ltd. access to a much larger R&D engine, helping identify and develop candidate compounds for inflammatory and other serious diseases. Shared work broadens scientific scope and can speed target validation and technical learning. This matters because Amgen is a top-tier biotech R&D spender, so the collaboration can raise Entera Bio Ltd.'s hit rate without building all expertise in-house.
- Access to external scientific expertise
- Broader disease and target coverage
- Faster validation, lower development risk
Entera Bio's Oral Delivery Test: Can the Platform Prove It?
Technological risk for Entera Bio Ltd. is still centered on oral delivery of fragile peptides and proteins, where even small absorption gains can change the whole program. EB612 is in Phase II and EB613 has moved to Phase I, so the key test is whether the platform can keep showing stable bioavailability, safety, and scalable manufacturing.
| Metric | Value |
|---|---|
| Oral semaglutide bioavailability | 0.4% to 1% |
| EB612 stage | Phase II |
| EB613 stage | Phase I |
Legal factors
Clinical trial compliance
Entera Bio Ltd.’s Phase I and Phase II studies must follow protocol, ethics approval, informed consent, and safety reporting rules; these trials often enroll only 20-100 patients, so one lapse can trigger a hold. Regulators can pause development fast if human-subject protections or adverse-event reporting fail. For a small biotech like Entera Bio Ltd., that legal risk can directly delay data readouts and raise trial costs.
Drug approval pathway
Entera Bio Ltd. cannot commercialize a product until regulators clear safety, efficacy, and manufacturing quality data. For an oral peptide or protein candidate, that usually means staged FDA and other agency reviews, with any CMC gap delaying filing or approval. This legally constrains timelines because Entera Bio must finish preclinical work, clinical trials, and process validation before launch. In practice, the drug approval pathway is a gate, not a formality.
Licensing agreement terms
Entera Bio Ltd.’s Amgen deal has both research and licensing terms, so the contract scope matters for who controls development, data, and follow-on rights. Milestone triggers, exclusivity, and IP ownership can change future cash flows and limit strategic freedom. In 2025 filings, these terms remained legally material because they can decide who keeps rights to resulting assets and who pays if goals are met.
Patent and IP protection
Entera Bio Ltd.’s oral large-molecule pipeline depends on strong patent coverage, because weak IP can cut partner interest and narrow pricing power. Patent scope shapes who can copy the platform and how much leverage Entera Bio Ltd. has in licensing talks. Any IP dispute could delay or block commercialization, which matters in a market where one failed legal claim can erase years of R&D value.
- Strong patents protect oral delivery economics.
- Broader scope lifts partner value.
- IP fights can delay commercialization.
Cross-jurisdiction operations
Entera Bio Ltd. faces cross-jurisdiction legal risk because it operates in Israel while working with US partners, so one project can trigger Israeli and US rules at the same time. Data handling, contracts, and regulatory filings may need to meet two legal systems, including privacy, export, and disclosure rules. That lifts compliance cost and can slow submissions.
- Dual legal review is often required.
- Privacy rules can differ by country.
- Contract terms need two-law checks.
Entera Bio’s Legal Risks Could Delay Trials and Erase Value
Entera Bio Ltd.’s legal risk sits in trial compliance, FDA/EMA filing rules, and contract control. In 2025 filings, its Amgen deal, patent scope, and cross-border data duties stayed key because they shape who owns rights, who pays milestones, and how fast assets can move. For a small biotech, one IP or ethics issue can delay data, raise costs, and weaken valuation.
| Legal factor | 2025 relevance |
|---|---|
| Trial compliance | Can trigger clinical holds |
| Patent scope | Protects oral delivery value |
| Amgen contract | Sets rights and milestones |
| Cross-border rules | Raises compliance cost |
Environmental factors
Low-volume lab footprint
Entera Bio remained clinical-stage in 2025, so its environmental footprint is far smaller than a commercial drug maker's. Most impact comes from lab work, clinical trial materials, and outsourced CMC manufacturing, not in-house plants. Waste handling is still key, especially for biohazard, solvent, and single-use supply waste.
Pharmaceutical waste control
Entera Bio Ltd. must manage chemical, biological, and sharps waste from biotech work under strict segregation and vendor controls. WHO says about 15% of healthcare waste is hazardous, so mislabeled bins or weak pickup oversight can quickly raise worker and environmental risk. Good control cuts spill, exposure, and disposal cost pressure.
Energy use in R&D
Entera Bio Ltd.’s R&D labs and cold-chain storage draw steady power, since temperature-sensitive samples need tight control day and night. Energy efficiency steps like better insulation, smart HVAC, and LED lighting can cut use by 20% to 30% in lab settings. That lowers operating costs and can also trim Scope 2 emissions.
Clinical supply logistics
Multi-site trials increase Entera Bio Ltd.'s logistics footprint because each site adds more trial-material shipments, packaging, and often temperature-controlled transport. More geography means more road and air freight, so transport emissions rise and waste from single-use packs grows. Tight supply planning, right-sized inventory, and fewer emergency reships can cut both cost and environmental load.
- More sites, more shipments
- Packaging waste rises fast
- Planning cuts emissions and waste
Climate and resilience risk
Jerusalem-based operations face rising climate stress, including hotter summers, water strain, and power or transport disruption that can slow labs, data systems, and trial work. For Entera Bio Ltd., business continuity planning is not optional: backup power, remote access, and site redundancy protect research timelines and sample integrity. Environmental resilience is now part of operational risk management, especially as extreme-heat and outage events can hit biotech workflows with little warning.
- Protect labs with backup power.
- Test data recovery and remote access.
- Map alternate trial coordination paths.
Entera Bio’s Light Footprint Hides Key Waste and Energy Risks
Entera Bio Ltd.’s environmental impact stayed light in 2025 because it remained clinical-stage, with no commercial plants to manage. Most risk sits in lab waste, cold-chain energy use, and outsourced trial logistics, where single-use packs and temperature control raise both waste and Scope 2 emissions. Climate stress in Jerusalem also makes backup power and remote access key for continuity.
| Factor | Key data |
|---|---|
| Hazardous healthcare waste | About 15% |
| Lab energy cuts | 20% to 30% |
| Main footprint drivers | Waste, cold chain, freight |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.